American Century Companies’s Denali Therapeutics DNLI Stock Holding History
Bought
Maintained
Sold
Other funds holding DNLI
BBA
American Century Companies's DNLI Position: Q2 2026 in Review
American Century Companies reduced its Denali Therapeutics (DNLI) stake by 24% in Q2 2026, selling an estimated $4.59M and leaving 712,526 shares worth $18.3M. The position accounts for 0.01% of the portfolio, ranked #1327.
American Century Companies first reported a position in DNLI in Q1 2019 and has held it in 30 quarters since. The position peaked at $27.2M in Q4 2020. 273 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.
- American Century Companies held 712,526 shares of Denali Therapeutics worth $18.3M as of Q2 2026.
- American Century Companies sold 223,166 Denali Therapeutics shares in Q2 2026, an estimated $4.59M.
- Denali Therapeutics made up 0.01% of American Century Companies's portfolio in Q2 2026, its #1327 holding.
- American Century Companies first reported a position in Denali Therapeutics in Q1 2019 and has held it in 30 quarters since.
- American Century Companies's Denali Therapeutics position peaked at $27.2M in Q4 2020.
- 273 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.
Based on American Century Companies's 13F filing for Q2 2026, filed 12 Aug 2026.